Patents by Inventor Chiang Jia Li

Chiang Jia Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11015195
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: May 25, 2021
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Xiangao Sun, Harry Rogoff, Youzhi Li
  • Patent number: 11001840
    Abstract: The present invention relates to the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle. A preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA. The nanoparticles of the present invention are also effective when administered orally.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 11, 2021
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Youzhi Li, Keyur Gada, Xiaoshu Dai
  • Publication number: 20210115006
    Abstract: The present invention relates to the composition and method of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 22, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Chiang Jia Li, Keith Mikule, Youzhi Li
  • Patent number: 10934309
    Abstract: This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N—R6; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; R1 and R2 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; and R6 is a hydrogen atom or an optionally-substituted C1-6 alkyl group, etc.].
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: March 2, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Hitoshi Ban, Seiji Kamioka, Shoukou Ri, Tomoyuki Furuta, Hiroyuki Kitano, Chiang Jia Li
  • Patent number: 10927376
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: February 23, 2021
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Xiangao Sun, Harry Rogoff, Youzhi Li
  • Publication number: 20210024482
    Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such corn pounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.
    Type: Application
    Filed: May 15, 2020
    Publication date: January 28, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Chiang Jia Li, Harry Rogoff, Youzhi Li, Jifeng Liu, Wei Li
  • Patent number: 10898469
    Abstract: The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: January 26, 2021
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Tsuguteru Otsubo, Eiji Sugaru, Hiroki Yamaguchi, Nobuyuki Sawada, Chiang Jia Li
  • Publication number: 20200397740
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: April 7, 2020
    Publication date: December 24, 2020
    Applicant: Sumitomo Dainnipon Pharma Oncology. Inc.
    Inventors: Chiang Jia Li, Wei Li, David Leggett, Youzhi Li, David Kerstein, Matthew Hitron
  • Publication number: 20200392098
    Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O)B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.
    Type: Application
    Filed: August 28, 2020
    Publication date: December 17, 2020
    Applicants: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Chiang Jia LI
  • Patent number: 10851075
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: December 1, 2020
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Patent number: 10800752
    Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O)B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: October 13, 2020
    Assignees: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Chiang Jia Li
  • Publication number: 20200268728
    Abstract: The present invention provides an anti-tumor agent comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein ring Q1 is optionally-substituted C6-10 aryl, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is C1-4 alkylene which may be optionally substituted with 1 to 3 fluorine atoms or C3-7 cycloalkyl; W2 is —NR4aC(O)—, etc. wherein R4a is hydrogen atom or C1-6 alkyl; ring Q2 is optionally-substituted C6-10 aryl, etc., in combination with at least one agent selected from the group consisting of an anti-cancer agent, an anti-diabetic agent, an agent for treating dyslipidemia, an agent for treating multiple sclerosis, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an anti-fungal agent, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 20, 2017
    Publication date: August 27, 2020
    Inventors: Yuichi Fukunaga, Erina Yamakawa, Eiji Sugaru, Satoshi Ikeda, Tsuguteru Otsubo, Hiroki Umehara, Chiang Jia Li
  • Publication number: 20200237711
    Abstract: The present disclosure provides pharmaceutical compositions, combinations, and uses thereof for treating and/or preventing cancer. For example, a pharmaceutical composition of the present disclosure can also include 2-acetylnaphtho[2,3-b]furan-4,9-dione, a prodrug thereof, a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutically acceptable solvate of any of the foregoing; and at least one excipient independently being a binder, a disintegrant, a lubricant, a surfactant, one other excipient, or a combination thereof. For example, a combination of the present disclosure can include 2-acetylnaphtho[2,3 b]furan-4,9-dione, a prodrug thereof, a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutically acceptable solvate of any of the foregoing; and at least one second agent independently being; a metabolic inhibitor, a transporter inhibitor, a NSAID, or a combination thereof.
    Type: Application
    Filed: September 27, 2019
    Publication date: July 30, 2020
    Inventors: Chiang Jia Li, Eiichiro Ogimura, Tetsuya Nakagawa, Eiji Sugaru, Nobuyuki Koike
  • Patent number: 10646464
    Abstract: Methods for treating advanced thymoma and thymic carcinoma in a subject comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I) (2-acetylnaphtho[2,3-b]furan-4,9-dione) as disclosed herein.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: May 12, 2020
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Youzhi Li, Wei Li, Matthew Hitron, Yuan Gao
  • Publication number: 20200071696
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Application
    Filed: March 11, 2019
    Publication date: March 5, 2020
    Inventors: Chiang Jia LI, Xiangao SUN, Harry ROGOFF, Youzhi LI
  • Publication number: 20200063128
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Application
    Filed: February 20, 2019
    Publication date: February 27, 2020
    Inventors: Chiang Jia LI, Xiangao SUN, Harry ROGOFF, Youzhi LI
  • Publication number: 20200039948
    Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.
    Type: Application
    Filed: December 31, 2018
    Publication date: February 6, 2020
    Inventors: Chiang Jia Li, Harry Rogoff, Youzhi Li, Jifeng Liu, Wei Li
  • Patent number: 10543189
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: January 28, 2020
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Wei Li, David Leggett, Youzhi Li, David Kerstein, Matthew Hitron
  • Publication number: 20190388382
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 26, 2019
    Inventors: Chiang Jia Li, Wei Li, David Leggett, Youzhi Li, David Kerstein, Matthew Hitron
  • Publication number: 20190262319
    Abstract: The invention provides thiazole-substituted indolin-2-ones as inhibitors of cancer stem cell pathway kinases (CSCPK) and related kinases, and methods of using these compounds, to treat subjects in need thereof.
    Type: Application
    Filed: October 25, 2018
    Publication date: August 29, 2019
    Inventors: Chiang Jia Li, Youzhi Li